The Lancet Respiratory Medicine, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Язык: Английский
Annals of Internal Medicine, Год журнала: 2024, Номер 177(3), С. 291 - 302
Опубликована: Март 1, 2024
Background: Some data suggest a higher incidence of diagnosis autoimmune inflammatory rheumatic diseases (AIRDs) among patients with history COVID-19 compared uninfected patients. However, these studies had methodological shortcomings. Objective: To investigate the effect on long-term risk for incident AIRD over various follow-up periods. Design: Binational, longitudinal, propensity-matched cohort study. Setting: Nationwide claims-based databases in South Korea (K-COV-N cohort) and Japan (JMDC cohort). Participants: 10 027 506 Korean 12 218 680 Japanese aged 20 years or older, including those between 1 January 2020 31 December 2021, matched to influenza infection control Measurements: The primary outcome was onset (per appropriate codes from International Classification Diseases, 10th Revision) 1, 6, months after respective index date Results: Between participants (mean age, 48.4 [SD, 13.4]; 50.1% men), 394 274 (3.9%) 98 596 (0.98%) influenza, respectively. After propensity score matching, beyond first 30 days infection, were at increased (adjusted hazard ratio, 1.25 [95% CI, 1.18 1.31]) influenza-infected 1.30 [CI, 1.02 1.59]). more severe acute COVID-19. Similar patterns observed cohort. Limitations: Referral bias due pandemic; residual confounding. Conclusion: SARS-CoV-2 associated without infection. greater severity Primary Funding Source: National Research Foundation Korea.
Язык: Английский
Процитировано
46
BMC Public Health, Год журнала: 2024, Номер 24(1)
Опубликована: Июль 4, 2024
Abstract Background Since the Coronavirus disease 2019 (COVID-19) pandemic began, number of individuals recovering from COVID-19 infection have increased. Post-COVID Syndrome, or PCS, which is defined as signs and symptoms that develop during after in line with COVID-19, continue beyond 12 weeks, are not explained by an alternative diagnosis, has also gained attention. We systematically reviewed determined pooled prevalence estimate PCS worldwide based on published literature. Methods Relevant articles Web Science, Scopus, PubMed, Cochrane Library, Ovid MEDLINE databases were screened using a Preferred Reporting Items for Systematic Reviews Meta-Analyses-guided systematic search process. The included studies English, January 2020 to April 2024, had overall one outcomes studied, involved human population confirmed diagnosis undergone assessment at weeks post-COVID beyond. As primary outcome measured, was estimated meta-analysis data extracted individual studies, conducted via random-effects model. This study been registered PROSPERO (CRD42023435280). Results Forty eight met eligibility criteria this review. 16 accepted worldwide, 41.79% (95% confidence interval [CI] 39.70–43.88%, I 2 = 51%, p 0.03). Based different follow-up timepoints acute infection, ≥ 3rd, 6th, 12th months each 45.06% CI: 41.25–48.87%), 41.30% 34.37–48.24%), 41.32% 39.27–43.37%), respectively. Sex-stratified 47.23% 44.03–50.42%) male 52.77% 49.58–55.97%) female. continental regions, 46.28% 39.53%-53.03%) Europe, 46.29% 35.82%-56.77%) America, 49.79% 30.05%-69.54%) Asia, 42.41% 0.00%-90.06%) Australia. Conclusion estimates could be used further comprehensive might enable development better management plans reduce effect health related economic burden.
Язык: Английский
Процитировано
28
Nature Medicine, Год журнала: 2025, Номер unknown
Опубликована: Янв. 8, 2025
Язык: Английский
Процитировано
2
Seminars in Immunology, Год журнала: 2024, Номер 72, С. 101873 - 101873
Опубликована: Март 1, 2024
Язык: Английский
Процитировано
14
Viruses, Год журнала: 2024, Номер 16(7), С. 1060 - 1060
Опубликована: Июнь 30, 2024
Since the emergence of SARS-CoV-2 virus in 2019, nearly 700 million COVID-19 cases and 7 deaths have been reported globally. Despite most individuals recovering within four weeks, Center for Disease Control (CDC) estimates that 7.5% to 41% develop post-acute infection syndrome (PAIS), known as 'Long COVID'. This review provides current statistics on Long COVID's prevalence, explores hypotheses concerning epidemiological factors, such age, gender, comorbidities, initial severity, vaccine interactions, delves into potential mechanisms, including immune responses, viral persistence, gut dysbiosis. Moreover, we conclude women, advanced non-vaccination, low socioeconomic status all appear be risk factors. The reasons these differences are still not fully understood likely involve a complex relationship between social, genetic, hormonal, other Furthermore, with seem more endure economic hardship due persistent symptoms. In summary, our findings further illustrate multifaceted nature COVID underscore importance understanding factors mechanisms needed effective therapeutic strategies interventions.
Язык: Английский
Процитировано
11
COVID, Год журнала: 2025, Номер 5(1), С. 11 - 11
Опубликована: Янв. 14, 2025
Background: The coronavirus disease 2019 (COVID-19) pandemic has generated profound health, societal, and economic consequences, which have been further compounded by long-term sequelae commonly referred to as post-COVID-19 or long-COVID syndrome. Understanding the real-world impact of mortality is therefore critical for effective healthcare planning resource allocation. Methods: A descriptive epidemiological study was conducted using data from US National Center Health Statistics identify deaths attributed condition, classified ICD-10 code U09.9, October 2021 December 2024. Demographic factors such gender, age, place death were also extracted. Results: By 2024, 2653 under corresponding an age-adjusted rate 0.089 × 100,000. Mortality significantly higher in males compared females (0.098 vs. 0.081 100,000; p < 0.001). clear age-related gradient observed, with rates increasing almost linearly advancing age. largest fraction occurred at home (33.0%), followed nursing homes (26.3%) medical facilities (24.1%). Conclusions: These findings highlight substantial yet complex condition on mortality, observed males, older adults, individuals home, highlighting need targeted interventions allocation, particularly these higher-risk groups.
Язык: Английский
Процитировано
1
Cytokine, Год журнала: 2025, Номер 189, С. 156884 - 156884
Опубликована: Фев. 22, 2025
Язык: Английский
Процитировано
1
MedComm, Год журнала: 2024, Номер 5(4)
Опубликована: Март 15, 2024
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently caused a global pandemic, resulting in more than 702 million people being infected and over 6.9 deaths. Patients with disease (COVID-19) may suffer from diarrhea, sleep disorders, depression, even cognitive impairment, which is associated long COVID during recovery. However, there remains no consensus on effective treatment methods. Studies have found that patients COVID-19 alterations microbiota their metabolites, particularly the gut, be involved regulation of immune responses. Consumption probiotics alleviate discomfort by inflammation oxidative stress. pathophysiological process underlying alleviation COVID-19-related symptoms complications targeting unclear. In current study, we summarize latest research evidence together SARS-CoV-2 vaccine use, focus relationship between use. This work provides probiotic-based interventions improve regulating gut systemic immunity. Probiotics also used as adjuvants to efficacy.
Язык: Английский
Процитировано
6
Journal of Primary Care & Community Health, Год журнала: 2024, Номер 15
Опубликована: Янв. 1, 2024
In addition to the morbidity and mortality associated with acute infection, COVID-19 has been persistent symptoms (>30 days), often referred as Long COVID (LC). LC cluster into phenotypes, resembling conditions such fibromyalgia, postural orthostatic tachycardiac syndrome (POTS), myalgic encephalomyelitis/chronic fatigue (ME/CFS). clinics have established best address needs of patients continuity care. We developed a cross-sectional survey assess treatment response through our Clinic (LCC).
Язык: Английский
Процитировано
5
Frontiers in Microbiology, Год журнала: 2024, Номер 15
Опубликована: Июль 15, 2024
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, is known to infect people all ages and both sexes. Senior populations have greatest risk severe sexual dimorphism in clinical outcomes has been reported. Neurological symptoms are widely observed COVID-19 patients, with many survivors exhibiting persistent neurological cognitive impairment. The present study aims investigate impact age sex on neuroinflammatory response SARS-CoV-2 infection using a mouse model. Wild-type C57BL/6J mice were intranasally inoculated lineage B.1.351, variant mice. Older male exhibited significantly greater weight loss higher viral loads lung at 3 days post infection. Notably, no RNA was detected brains infected Nevertheless, expression IL-6, TNF-α, CCL-2 brain increased RNA-seq transcriptomic analysis showed that caused significant changes gene profiles, implicating innate immunity, defense virus, cerebrovascular neuronal functions. These findings demonstrate triggers response, despite lack detectable virus brain. Aberrant activation immune disruption blood-brain barrier endothelial cell integrity, suppression activity axonogenesis underlie Understanding role these affected pathways pathogenesis helps identify appropriate points therapeutic interventions alleviate dysfunction during COVID-19.
Язык: Английский
Процитировано
4